Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma

Hepatology

Volumn 58, Issue 1, 2013, Pages 139-149

  Fu, Junliang ^a,b   Zhang, Zheng ^b   Zhou, Lin ^b   Qi, Zhaorui ^b   Xing, Shaojun ^b   Lv, Jiyun ^b   Shi, Jianfei ^b   Fu, Baoyun ^b   Liu, Zhenwen ^b   Zhang, Ji Yuan ^b   Jin, Lei ^b   Zhao, Yulai ^b   Lau, George K K ^b   Zhao, Jingmin ^b   Wang, Fu Sheng ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME A; GRANZYME B; PERFORIN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL RENEWAL; CHRONIC HEPATITIS; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME SYNTHESIS; EXOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR RECURRENCE;

ADULT; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PORE FORMING CYTOTOXIC PROTEINS; PROGNOSIS; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84879607470     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26054     Document Type: Article

References (41)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, et al. Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev 2003; 12: 273-279.
3. Appay V. The physiological role of cytotoxic CD4(+) T-cells: the holy grail? Clin Exp Immunol 2004; 138: 10-13.
4. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008; 20: 339-343.
5. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168: 5954-5958.
6. Soghoian DZ, Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 2010; 9: 1453-1463.
7. + T cells: ready for direct attack. J Exp Med 2006; 203: 805-808.
8. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262: 89-95.
9. + T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses. J Immunol 2007; 179: 1303-1312.
10. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 2000; 95: 2352-2355.
11. + T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood 2007; 109: 2049-2057.
12. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650.
13. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-667.
14. +, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004; 103: 2238-2247.
15. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006; 13: 505-514.
16. +, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173: 1834-1841.
17. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998; 41: 2108-2116.
18. - T cells in ankylosing spondylitis. Arthritis Res Ther 2003; 5: R292-300.
19. + T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004; 89: 435-443.
20. + T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001; 126: 29-36.
21. + cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 2005; 115: 451-461.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
23. Sheng JM, Zhao WH, Wu FS, Ma ZM, Feng YZ, Zhou XR, et al. The Chinese classification system compared with TNM staging in prognosis of patients with primary hepatic carcinoma after resection. Hepatobiliary Pancreat Dis Int 2005; 4: 561-564.
24. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
25. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747.
26. Chen X, Wang B, Chang LJ. Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cell Immunol 2006; 243: 10-18.
27. + T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865-2877.
28. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593.
29. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354.
30. + T cells in cancer immunotherapy. Immunotherapy 2010; 2: 607.
31. + T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
32. Weiner LM. Cancer immunotherapy-the endgame begins. N Engl J Med 2008; 358: 2664-2665.
33. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129: 428-437.
34. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. HEPATOLOGY 2005; 41: 722-730.
35. + T cells. J Immunol 1997; 159: 2091-2099.
36. null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007; 179: 6514-6523.
37. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-989.
38. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
39. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
40. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
41. Wong P, Pamer EG. Feedback regulation of pathogen-specific T cell priming. Immunity 2003; 18: 499-511.